US-based biotechnology company Novavax on Friday announced that its Covid-19 vaccine showing 89.3% effective in preventing Covid-19 in a trial conducted in the UK.
The study assessed the efficacy of the vaccine — NoVavaX-CoV2373 — during a period with high transmission and with a new UK variant strain of the virus emerging and circulating widely.
“NoVavaX-CoV2373 has the potential to play key role in solving this global public health crisis. We are looking forward to continuing to work with our partners, collaborators, investigators and regulators around the world to make the vaccine available as soon as possible,” Stanley C. Erck, President and Chief Executive Officer, Novavax, said in a statement.
The biotech company also announced results of its Phase 2b study conducted in South Africa.
In the South Africa Phase 2b clinical trial, 60 per cent efficacy for the prevention of mild, moderate and severe Covid-19 disease was observed in the 94 per cent of the study population that was HIV-negative.
“The 60 per cent reduced risk against Covid-19 illness in vaccinated individuals in South Africans underscores the value of this vaccine to prevent illness from the highly worrisome variant currently circulating in South Africa, and which is spreading globally,” said Shabir Maddi, principal investigator in the Novavax COVID-19 vaccine trial in South Africa.
In 2020, Novavax had announced its deal with Pune-based vaccine manufacturing company Serum Institute of India (SII) in order to produce 2 billion doses of Covid-19 vaccines.
The UK study enrolled more than 15,000 participants between 18-84 years of age, including 27 per cent over the age of 65.
The primary endpoint of the UK Phase 3 clinical trial is based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) Covid-19 with onset at least 7 days after the second study vaccination in serologically negative adult participants at baseline.
The first interim analysis is based on 62 cases, of which 56 cases of Covid-19 were observed in the placebo group versus 6 cases observed in the NVX-CoV2373 group, resulting in a point estimate of vaccine efficacy of 89.3 per cent.
Of the 62 cases, 61 were mild or moderate, and 1 was severe (in placebo group).
Primary analysis indicates that the UK variant strain that was increasingly prevalention was detected in over 50 per cent of the PCR-confirmed symptomatic cases (32 UK variant, 24 non-variant, 6 unknown).
The interim analysis included a primary review of the safety database, which seems that severe and medically attended adverse events occurred at low levels and were balanced between vaccine and placebo groups.
